S Neubauer1, T Schilling2, J Zeidler3, A Lange3, S Engel4, R Linder4, F Verheyen4, J-M Graf von der Schulenburg3, A Haverich2. 1. Leibniz Universität Hannover, Center for Health Economics Research Hannover (CHERH), Hannover, Deutschland. sn@cherh.de. 2. Medizinische Hochschule Hannover, Klinik für Herz-, Thorax-, Transplantations- und Gefäßchirurgie (HTTG), Hannover, Deutschland. 3. Leibniz Universität Hannover, Center for Health Economics Research Hannover (CHERH), Hannover, Deutschland. 4. Techniker Krankenkasse, Wissenschaftliches Institut für Nutzen und Effizienz im Gesundheitswesen (WINEG), Hamburg, Deutschland.
Abstract
BACKGROUND: The German national guidelines on chronic heart failure provide treatment recommendations to physicians and reflect the current level of evidence; however, it is questionable to what extent these recommendations are applied in the routine practice and what the effect of guideline adherence on mortality is. METHODS: In this study the claims data of a major German health insurance fund collected over a period of 4 years were analyzed. Using binary logistic regression and Cox regression analyses the influence of drug prescriptions, diagnostic measures, influenza vaccination, the New York Heart Association (NYHA) status, the age and gender on mortality were examined. RESULTS: The study population consisted of 85,465 heart failure patients. Approximately 60 % of the drugs were prescribed according to the guidelines. There was a positive correlation between a higher NYHA status and mortality with an odds ratio (OR) of 3.264. Especially pharmacotherapy with angiotensin-converting enzyme (ACE) inhibitors and beta blockers according to the guidelines was associated with a lower mortality rate (OR 0.448 resp. 0.444). Also patients diagnosed using echocardiography at regular intervals showed a lower risk of dying (OR 0.314). CONCLUSION: The results of this large sample could confirm the results of clinical trials that a therapy according to the guidelines has a significant impact on mortality. By analyzing the claims data evidence was found that in the treatment of heart failure patients the medical results could be improved by adherence to guideline recommendations.
BACKGROUND: The German national guidelines on chronic heart failure provide treatment recommendations to physicians and reflect the current level of evidence; however, it is questionable to what extent these recommendations are applied in the routine practice and what the effect of guideline adherence on mortality is. METHODS: In this study the claims data of a major German health insurance fund collected over a period of 4 years were analyzed. Using binary logistic regression and Cox regression analyses the influence of drug prescriptions, diagnostic measures, influenza vaccination, the New York Heart Association (NYHA) status, the age and gender on mortality were examined. RESULTS: The study population consisted of 85,465 heart failurepatients. Approximately 60 % of the drugs were prescribed according to the guidelines. There was a positive correlation between a higher NYHA status and mortality with an odds ratio (OR) of 3.264. Especially pharmacotherapy with angiotensin-converting enzyme (ACE) inhibitors and beta blockers according to the guidelines was associated with a lower mortality rate (OR 0.448 resp. 0.444). Also patients diagnosed using echocardiography at regular intervals showed a lower risk of dying (OR 0.314). CONCLUSION: The results of this large sample could confirm the results of clinical trials that a therapy according to the guidelines has a significant impact on mortality. By analyzing the claims data evidence was found that in the treatment of heart failurepatients the medical results could be improved by adherence to guideline recommendations.
Authors: Josef Stehlik; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Jason D Christie; Anne I Dipchand; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Marshall I Hertz Journal: J Heart Lung Transplant Date: 2012-10 Impact factor: 10.247
Authors: Sean Collins; Alan B Storrow; Nancy M Albert; Javed Butler; Justin Ezekowitz; G Michael Felker; Gregory J Fermann; Gregg C Fonarow; Michael M Givertz; Brian Hiestand; Judd E Hollander; David E Lanfear; Phillip D Levy; Peter S Pang; W Frank Peacock; Douglas B Sawyer; John R Teerlink; Daniel J Lenihan Journal: J Card Fail Date: 2014-07-18 Impact factor: 5.712
Authors: Michel Komajda; Pablo Lapuerta; Nancy Hermans; José Ramon Gonzalez-Juanatey; Dirk J van Veldhuisen; Erland Erdmann; Luigi Tavazzi; Philip Poole-Wilson; Claude Le Pen Journal: Eur Heart J Date: 2005-04-12 Impact factor: 29.983
Authors: William Frank Peacock; Charles Emerman; Maria R Costanzo; Deborah B Diercks; Margarita Lopatin; Gregg C Fonarow Journal: Congest Heart Fail Date: 2009 Nov-Dec
Authors: W von Scheidt; C Zugck; M Pauschinger; R Hambrecht; O Bruder; A Hartmann; M Rauchhaus; R Zahn; J Brachmann; U Tebbe; T Neumann; R H Strasser; M Böhm; S Störk; M Hochadel; P Heidemann; J Senges Journal: Clin Res Cardiol Date: 2014-07-23 Impact factor: 5.460
Authors: Maria Pufulete; Rachel Maishman; Lucy Dabner; Julian P T Higgins; Chris A Rogers; Mark Dayer; John MacLeod; Sarah Purdy; William Hollingworth; Morten Schou; Manuel Anguita-Sanchez; Patric Karlström; Michael Kleiner Shochat; Theresa McDonagh; Angus K Nightingale; Barnaby C Reeves Journal: Syst Rev Date: 2018-07-31